Webinar: Disrupting the Solid Tumor Environment Using CAR Get Access NowHomepage Applications Cell and Gene Therapy Cell Therapy Cell Therapy Research & Development Resources
Presenters:Prasad AdusumilliDeputy Chief and Attending, Thoracic Surgery; Vice Chair, Department of Surgery; Head, Solid Tumors Cell Therapy; Cellular Therapeutics Center Director, Mesothelioma Program; Memorial Sloan-Kettering Cancer Center, NYLeonid MetelitsaCo-director, Neuroblastoma Program; Professor, Department of Pediatrics, Section of Hematology/Oncology; Baylor College of MedicineStephen GottschalkChair, Department of Bone Marrow Transplantation and Cellular Therapy; Endowed Chair in Bone Marrow Transplantation and Cellular Therapy; Member St. Jude Faculty  

Two FDA-approved CAR T immunotherapies, Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel), for cancers of the blood have ushered in a new era in the development of gene and cell therapies.  The engineered CARs are designed to recognize CD19 antigen on the blood tumor cells, which allows the CAR-expressing T cell to target them for destruction. Previous clinical trials testing these agents showed striking effects in patients, leading to high rates of remission and, in many cases, complete recovery. Efforts are now underway to exploit CAR T and related adoptive cell immunotherapy technology (ACT) to treat solid tumors—tumors which have so far proven largely resistant to treatment with these agents. Our immune system detects and destroys abnormal cells, including tumors. Patients whose tumors harbor tumor-infiltrating lymphocytes (TILs) often fare better than those whose tumors do not. However, most patients lack a significant tumor-reactive immune infiltrate, and the tumor environment itself can be inherently immunosuppressive. Moreover, identification of tumor-specific antigens that can be safely and selectively targeted has been a challenge. In this webinar, Prasad Adusumilli, Stephen Gottschalk, and Leonid Metelitsa discuss the challenges of targeting CAR T and related ACT platforms to the solid tumor environment, and they provide examples of how combining gene and cell therapy with checkpoint inhibition and other strategies may enable us to disrupt the tumor environment and its dynamic response to such therapies.   

To learn more about information-rich solutions for CAR-T research from Sartorius, visit
www.sartorius.com/car-t-research.
 

Register and Watch the Webinar Now

  • Clear form data

Complete The Form Below To Access This Webinar Recording

First Name *Last Name *
E-Mail *
Company *
Postal Code *
Country * --Select-- Afghanistan Aland Islands Albania Algeria Andorra Anguilla Antigua and Barbuda Angola Antarctica Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Barbados Bangladesh Belgium Belize Bermuda Benin Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bouvet Island Bosnia & Herzegovina Botswana Brazil British Indian Ocean Territory Brunei Darussalam Burkina Faso Bulgaria Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Chad Chile China Chinese Taipei Cocos (Keeling) Islands Congo, the Democratic Republic of the Central African Republic Christmas Island Colombia Comoros Congo Cook Islands Cote d'Ivoire Costa Rica Croatia Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Eritrea Estonia Ethiopia Equatorial Guinea Falkland Islands (Malvinas) Faeroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Germany Grenada Georgia Guernsey Ghana Gibraltar Greenland Guinea Guadeloupe Greece Guatemala Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Indonesia Ireland Israel Isle of Man India Iraq Iceland Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Republic of Kyrgyzstan Kuwait Lao People's Democratic Republic Lebanon Liechtenstein Liberia Lesotho Lithuania Luxembourg Latvia Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Morocco Monaco Moldova, Republic of Montenegro Mongolia Montserrat Mozambique Micronesia Myanmar Namibia Nauru Nepal Netherlands New Caledonia Nicaragua Niger Nigeria Niue Norfolk Island Norway New Zealand Oman Pakistan Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Pierre and Miquelon Saint Kitts & Nevis Saint Lucia Saint Martin (French part) Saint Vincent and the Grenadines Samoa San Marino Sao Tome & Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sweden Svalbard and Jan Mayen Somalia Suriname Swaziland Switzerland Tajikistan Tanzania, United Republic of Thailand Timor-Leste Tokelau Togo Tonga Trinidad and Tobago Turkmenistan Turks and Caicos Tunisia Turkey Tuvalu Ukraine Uganda United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Virgin Islands, British Viet Nam Wallis & Futuna Western Sahara Yemen Zambia Zimbabwe Other, please indicate in the comment
What would be most helpful as you evaluate new solutions to your cell therapy challenges? * -- Select -- Speak to a CAR-T therapy consultant Schedule a demo of a CAR-T Solution Receive pricing information Receive literature to review I face no challenges in my process
* These fields are required Information on the use of your data can be found in our  privacy policy Get Access Now
Complete The Form Below To Access This Webinar Recording